Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

DIsney says it has sold out all commercial inventory for Sunday's Oscars, and notes packages include TV, streaming, social ...

Full year 2024 revenue of $807 million, exceeding guidance - - All 2024 clinical and regulatory milestones were achieved on schedule, including four NDA submissions ...

PTC Therapeutics Inc (PTCT) surpasses revenue expectations, strengthens cash position, and prepares for multiple product ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Despite a decline in total revenue, Schrodinger Inc (SDGR) showcases robust software performance and strategic collaborations ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...

Reports Q4 revenue $88.3M, consensus $83.2M. “We are delighted with Schrodinger’s (SDGR) excellent financial performance in 2024. Software ...

The CAR T-cell therapy market size was valued at $2.6 billion in 2022 & is estimated to hit $35.9 billion by 2032, exhibiting a CAGR of 28 ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...